Summary
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) ten-fold above that of LEV and also shows an ability to inhibit Na+ channels. This correlates with a higher potency in suppressing epileptiform responsesin vitro and a more potent and complete suppression of different seizure types in animals with an acquired or genetic epilepsy. Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program. It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract. Carcinogenicity studies are ongoing. Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability. Brivaracetam is primarily metabolized via hydrolysis of the acetamide group and CYP2C8-mediated hydroxylation. Its metabolites are not pharmacologically active. Excretion of over 95% of the dose, including metabolites, occurs renally within 72 h. Healthy volunteer studies demonstrated a favorable tolerability profile. Treatment emergent adverse events were mild to moderate, mostly of CNS origin, and resolved within 24 hrs, with decreasing incidence after repeated intake. Drug-drug interaction studies with high dose of brivaracetam (400 mg/d) showed a dose-dependent increase of carbamazepine-epoxide levels. No significant interaction with low doses of phenytoin was observed at the same high dose levels of brivaracetam, and only a moderate pharmacokinetic interaction with an oral contraceptive, without impact on hormonal levels or ovulation, was observed. The pharmacokinetic profile of brivaracetam is unaltered in elderly subjects or those with impaired renal function. Clearance of brivaracetam is reduced in patients with hepatic insufficiency. In the photoparoxysmal response model in patients with photosensitive epilepsy brivaracetam was effective at all tested doses (10 – 80 mg) in reducing or abolishing EEG discharges evoked by a photic stimulus. Phase 2 studies in patients with refractory partial onset seizures have recently been completed.
Key Words: Brivaracetam, UCB 34714, synaptic vesicle protein 2A, SV2A
References
- 1.Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proc Natl Acad Sci. 1999;96:15268–15273. doi: 10.1073/pnas.96.26.15268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lynch B, Lambeng N, Nocka K, et al. The Synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Roc Natl Acad Sci. 2004;101:9861–9866. doi: 10.1073/pnas.0308208101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Journal of Medicinal Chemistry. 2004;47:530–549. doi: 10.1021/jm030913e. [DOI] [PubMed] [Google Scholar]
- 4.Zona C, Pieri M, Klitgaard H, Margineanu D-G. ucb 34714, a new pyrrolidone derivative, inhibits Na+-currents in rat cortical neurons in culture. Epilepsia. 2004;45(suppl 7):146–146. [Google Scholar]
- 5.Margineanu D-G, Kenda BM, Michel P, Matagne AC, Klitgaard H. ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Epilepsia. 2003;44(suppl 9):261–261. [Google Scholar]
- 6.Margineanu D-G, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42:281–285. doi: 10.1006/phrs.2000.0689. [DOI] [PubMed] [Google Scholar]
- 7.Matagne AC, Kenda BM, Michel P, Klitgaard H. ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo. Epilepsia. 2003;44(suppl 9):260–260. [Google Scholar]
- 8.Mazarati AM, Wasterlain CG, Sankar R, Shin D. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res. 1998;801:251–253. doi: 10.1016/S0006-8993(98)00606-4. [DOI] [PubMed] [Google Scholar]
- 9.Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;14:179–185. doi: 10.1016/S0006-8993(98)01080-4. [DOI] [PubMed] [Google Scholar]
- 10.Wasterlain CG, Suchomelova L, Matagne AC, Klitgaard H, Mazarati AM, Shinmei S, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46(suppl 8):219–219. [Google Scholar]
- 11.Rolan P, Pigeolet E, Stockis A. Ucb 34714: single and multiple rising dose safety, tolerability, and pharmacokinetics in healthy subjects. Epilepsia. 2004;45(suppl 7):314–315. [Google Scholar]
- 12.Sargentini-Maier ML, Rolan P, Connell J, et al. Brivaracetam safety, tolerability, pharmacokinetics and CNS pharmacodynamic effects after 10 to 1400 mg single rising oral doses in healthy males. Br J Clin Pharmacol 2006 (in press).
- 13.Potter JM, Donnelly A. Carbamazepine-10, 11-Epoxide in Therapeutic Drug Monitoring. Ther Drug Monit. 1998;20:652–657. doi: 10.1097/00007691-199812000-00012. [DOI] [PubMed] [Google Scholar]
- 14.Kasteleijn-Nolst Trenité DGA, Parain D, Masnou P, Genton P, Steinhoff J, Hirsch E. Proof of principle in the new AED ucb 34714: use of the photosensitivity model. Epilepsia. 2004;45(suppl 7):309–309. [Google Scholar]